Roche Enters Licensing Agreement With Sarepta Therapeutics for Gene Therapy

   By Cristina Roca

Roche Holding AG (RO.EB) said Monday that it has struck a licensing deal with Sarepta Therapeutics Inc. (SRPT) for the exclusive right to launch and commercialize a gene therapy used for patients with Duchenne muscular dystrophy outside the U.S.

The Swiss pharmaceutical company said it will pay Sarepta an upfront $750 million in cash and $400 million in equity at closing, which is expected in the first quarter of 2020, for the rights to its SRP-9001 investigational gene therapy.

Sarepta is also eligible to receive regulatory and sales milestones of up to $1.7 billion, plus royalties on net sales, Roche said. The two companies will also share global development expenses.

Write to Cristina Roca at cristina.roca@dowjones.com

(END) Dow Jones Newswires

December 23, 2019 02:10 ET (07:10 GMT)

Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024